(MedPage Today) — Diabetes patients with hepatocellular carcinoma (HCC) experienced longer time to HCC recurrence and longer survival when they initiated a GLP-1 agonist rather than a DPP-4 inhibitor, a target trial emulation study found. (Gut…
Source: MedPage Today — Headlines
